|
|
| |
| |
 |
 |
ImQuest BioSciences, a leading anti-infective, anti-cancer and inflammatory disease research and drug development service provider, has a proven track record in providing the support required to effectively move compounds from the discovery phase through to preclinical IND-enabling studies for human clinical trials. ImQuest preclinical data has been included in dozens of INDs submitted by biotechnology and pharmaceutical clients for anti-infective and anti-cancer applications.
Diverse capabilities. Multidisciplinary approaches.
ImQuest’s diverse professional and technical capabilities permit the rapid evaluation of the biological, immunological and biochemical effects of therapeutics, including drugs, vaccines, natural products, gene therapy products and other biologics. A multidisciplinary approach to infectious disease, cancer and inflammatory disease research allows for the rapid development of the technologically current and novel programs that are required to overcome development obstacles. |
 |
Consulting approach. Uncompromised results.
ImQuest realizes the importance of establishing collaborative relationships in diverse areas of drug discovery. Years of experience in the discovery of new biologics and an intimate understanding of FDA requirements for approval make ImQuest an ideal product development partner.
The ImQuest staff, selected for their understanding of the biotech field and therapeutic development, use specialized knowledge to direct well-designed studies that are fully harmonized with the practices critical to the success of a new therapeutic candidate. ImQuest’s dedicated discovery team will design a strategic scientific program that includes everything needed to efficiently progress new product development. Experienced project leaders will manage risk, track progress and ensure client satisfaction with each phase of the process. |
|
Infectious Disease
Following the Points to Consider documents of the Food & Drug Administration, ImQuest will evaluate the efficacy, toxicity, range, and mechanism of action of test molecules in cell-based, biochemical and molecular assays. These compounds can also be evaluated in combination with other approved and experimental inhibitors and tested for resistance development potential. Analyses include in vitro selection, phenotypic and genotypic characterization of drug resistant viruses, and the evaluation of resistance engendering mutations on viral fitness. Customized assay development capabilities allow evaluation of test compounds in ways that focus on specific mode of action.
 |
HIV and immunodeficiency viruses |
|
Respiratory and enteric viruses |
|
Hepatitis B and C |
|
Bacteria |
|
Herpesviruses |
|
Fungi |
|
|
Cancer
With extensive experience in the development of anti-cancer agents, ImQuest employs a diverse panel of human cell lines to evaluate compounds for selective antiproliferative and cytotoxic activity. Cell-based, biochemical, and enzymatic capabilities are used to address each step of the pre-clinical drug development pathway, novel assays derived to explore molecular anti-cancer targets, and expertise utilized to develop assays for the in vitro evaluation of therapeutic agents on intact cells and the functional immune system. Xenograft and other customized animal models are used to provide a rationale for clinical development.
|
Antiproliferative and clonogenic assays |
|
Rodent-human xenograft and hollow-fiber models |
|
In vitro cytotoxicity and immunotoxicity |
|
Pharmacokinetics |
|
Biochemical, cellular and molecular mechanism of action |
|
Immunotherapeutic evaluations |
|
|
Immunoassay Development, Optimization & Validation
ImQuest expertise in immunology and assay development permits the rapid evaluation of immune modulation by therapeutics targeted at infectious disease or cancer. Novel immunoassays - cell based or biochemical - allow precise and robust detection of biologics, as well as their immunogenicity and neutralization. Functional immune assays measure the effects of therapeutic intervention on cellular, humoral and innate immunity.
|
ELISA development and optimization |
|
Cellular immune function |
|
Bioassays |
|
Innate immune function |
|
GLP validation |
|
Cytokine gene expression |
|
Neutralization assays |
|
ELISPOT and intracellularcytokine staining |
|
Humoral immune function |
|
|
|
|
| Services |
The research and development programs of ImQuest BioSciences require a detailed understanding of microbiology, cell biology, molecular biology, biochemistry, enzymology and immunology as they apply to the myriad of therapeutic development projects that are performed in our laboratories. Our expertise in these core scientific areas permits us to provide value-added and additional service based support to our clients in the form of technical and professional services for research and therapeutic product development. Bench top services include those involving virology, microbiology, tissue culture/cell biology, biochemistry, enzymology and immunology. In addition, ImQuest staff are highly adept at providing professional services including research and development consulting support, grant and contract writing support and Investigational New Drug and other regulatory services support.
|
|
|
| |
| |
| Copyright © 2006, ImQuest BioSciences. | | | |
| | | | | |
| | | | |
| |
|
|
